Tumor Microenvironment‐Specific Driven Nanoagents for Synergistic Mitochondria Damage‐Related Immunogenic Cell Death and Alleviated Immunosuppression
Small Methods · 2024
DOI: 10.1002/smtd.202301231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2024. Verfasst von Yanrong Qian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Research Institute, Shandong University, Shenzhen, 518057, P. R. China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Mitochondria, Immunogenic Cell Death, Nanoparticles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Postdoctoral Innovation Project, Postdoctoral Research Foundation of China.
Abstract (Originalsprache)
Despite significant breakthroughs in immunotherapy, the limitations of inadequate immune stimulation and stubborn immune resistance continue to present opportunities and challenges. Therefore, a two‐pronged approach, encompassing the activation of immunogenic cell death (ICD) and blocking the indoleamine 2,3‐dioxygenase (IDO)‐mediated pathway, is devised to elicit systemic anti‐tumor immunity and alleviate immunosuppression. Herein, a tumor microenvironment (TME)‐specific driven nanoagent is composed of a tetrasulfide bond‐bridged mesoporous silica layer (MON) coated up‐conversion nanoparticles as a nano‐carrier, combines Fe 2+ , curcumin, and indoximod for operating chemodynamic therapy/chemotherapy/immunotherapy. The consumption of glutathione (GSH) caused by MON degradation, the Fenton reaction of Fe 2+ , and curcumin triggering mitochondrial damage collectively exacerbate the oxidative stress, leading to a violent immunoreaction and reversal of the immunosuppressive TME through a combination of IDO‐inhibitors. Meanwhile, upconversion luminescence (UCL) imaging serves as a significant guiding tool for drug delivery and the treatment of nanoagents. In vivo and in vitro experiment results demonstrate that the nanosystem not only effectively inhibits the growth of primary tumors but also induces immune priming and memory effects to reject re‐challenged tumors. The strategy as a complementary approach displays great potential for future immunotherapy along with other multimodal treatment modes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Research Institute, Shandong University, Shenzhen, 518057, P. R. China.
- Institute of Molecular Sciences and Engineering, Institute of Frontier and Interdisciplinary Science, Shandong University, Qingdao, 266237, P. R. China.
ORCID-Profile: Chunxia Li
Förderung
- National Natural Science Foundation of China
- Shandong Postdoctoral Innovation Project
- Postdoctoral Research Foundation of China
- Natural Science Foundation of Shandong Province
- Taishan Scholar Foundation of Shandong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Qian, Y., Chen, W., Wang, M., Xie, Y., Qiao, L., Sun, Q., Gao, M., & Li, C. (2024). Tumor Microenvironment‐Specific Driven Nanoagents for Synergistic Mitochondria Damage‐Related Immunogenic Cell Death and Alleviated Immunosuppression. Small Methods. https://doi.org/10.1002/smtd.202301231
Vancouver
Qian Y, Chen W, Wang M, Xie Y, Qiao L, Sun Q, et al. Tumor Microenvironment‐Specific Driven Nanoagents for Synergistic Mitochondria Damage‐Related Immunogenic Cell Death and Alleviated Immunosuppression. Small Methods. 2024. doi:10.1002/smtd.202301231
BibTeX
@article{Qian2024,
author = {Qian, Yanrong and Chen, Weilin and Wang, Man and Xie, Yulin and Qiao, Luying and Sun, Qianqian and Gao, Minghong and Li, Chunxia},
title = {Tumor Microenvironment‐Specific Driven Nanoagents for Synergistic Mitochondria Damage‐Related Immunogenic Cell Death and Alleviated Immunosuppression},
journal = {Small Methods},
year = {2024},
doi = {10.1002/smtd.202301231}
}
EUVIMED